Disease · EFO_0007634

major depressive episode

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. major depressive episode. Diseases, record EFO_0007634. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007634

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: major depressive episode
Open Targets ID: EFO_0007634
Highest stage of its drugs: Phase 3, for 13 of its 37 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
KETAMINE	CHEMBL742	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ARMODAFINIL	CHEMBL1201192	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ESCITALOPRAM	CHEMBL1508	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LITHIUM CARBONATE	CHEMBL1200826	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LUMATEPERONE	CHEMBL3306803	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
QUETIAPINE	CHEMBL716	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
QUETIAPINE FUMARATE	CHEMBL3188993	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DESVENLAFAXINE SUCCINATE	CHEMBL1201728	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LACOSAMIDE	CHEMBL58323	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets57

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Sodium-dependent serotonin transporter	7	Serotonin transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	6	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	4	Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	3	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets
THRA	Thyroid hormone receptor	3	Thyroid hormone receptor agonist	Phase 2/3	https://conductscience.org/library/genes/7067	Drugs and targets
THRB	Thyroid hormone receptor	3	Thyroid hormone receptor agonist	Phase 2/3	https://conductscience.org/library/genes/7068	Drugs and targets
ADRA2A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
GABRA1	GABA-A receptor; anion channel	2	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets

1 to 10 of 57

See all 57 targets

Trials39

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02600494	Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression	Phase 3	554	2025-11-03	Bipolar Depression	LUMATEPERONE	Its record names the disease	ClinicalTrials.gov
NCT01072929	A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder	Phase 3	433	2015-01-26	Depression	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT01725308	A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes	Phase 2/3	431	2017-02-08	Bipolar Disorder	QUETIAPINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00883493	Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression	Phase 3	421	2012-06-29	Acute Bipolar Depression	LITHIUM CARBONATE, QUETIAPINE FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT00481195	Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder	Phase 2	257	2010-12-20	Bipolar I Depression	ARMODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT01001559	Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis		242	2013-12-19	Major Depressive Disorder	LEVOMEFOLIC ACID, NOREPINEPHRINE, SEROTONIN	Its record names the disease	ClinicalTrials.gov
NCT00946998	Chronic Kidney Disease Antidepressant Sertraline Trial	Phase 3	201	2018-01-30	Chronic Kidney Disease, Depression	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00367341	Imaging Predictors of Treatment Response in Depression	Not applicable	82	2014-01-09	Major Depressive Disorder	ESCITALOPRAM	Its record names the disease	ClinicalTrials.gov
NCT03051256	Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD	Phase 2	62	2021-03-17	Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant	ESMETHADONE	Its record names the disease	ClinicalTrials.gov
NCT01208324	Estrogen and Serotonin on Changing Brain Chemistry	Not applicable	47	2021-04-02	Menopause	ESTRADIOL, FLUOXETINE, TRYPTOPHAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 39

See all 39 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Quetiapine XR vs Quatiapine XR + Lithium: serious adverse events	5 of 212	5 of 209	421	NCT00883493	Trial comparisons
Armodafinil 150 mg/Day vs Placebo: serious adverse events	3 of 126	3 of 125	251	NCT00481195	Trial comparisons
Deplin + Antidepressant vs Antidepressant Alone: Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline	17 of 95	10 of 147	242	NCT01001559	Trial comparisons
Deplin + Antidepressant vs Antidepressant Alone: serious adverse events	1 of 93	3 of 103	196	NCT01001559	Trial comparisons
Sertraline vs Placebo: deaths from any cause	0 of 97	0 of 96	193	NCT00946998	Trial comparisons
Sertraline vs Placebo: serious adverse events	13 of 97	13 of 96	193	NCT00946998	Trial comparisons
Escitalopram vs Cognitive Behavioral Therapy: serious adverse events	0 of 42	0 of 40	82	NCT00367341	Trial comparisons
Escitalopram vs Cognitive Behavioral Therapy: Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks	12 of 32	12 of 31	63	NCT00367341	Trial comparisons
Escitalopram vs Cognitive Behavioral Therapy: Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks	18 of 32	18 of 31	63	NCT00367341	Trial comparisons
Depressed vs Healthy Controls: serious adverse events	0 of 17	0 of 9	26	NCT00896441	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37592013	RESULT	1	PubMed
36821775	RESULT	1	PubMed
34933568	RESULT	1	PubMed
29101402	RESULT	1	PubMed
25099397	RESULT	1	PubMed
23760393	RESULT	1	PubMed
23085503	RESULT	1	PubMed
21311704	RESULT	1	PubMed
20616670	RESULT	1	PubMed
42248535	DERIVED	1	PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0007634

GET https://conductscience.org/api/diseases/v1/EFO_0007634/drugs?page=2

API reference For AI assistants